November 2, 2026 · American journal of respiratory and critical care medicine · DOI: 10.1093/ajrccm/aamag572

Dupilumab is associated with improved lung functions in patients with COPD and type 2 inflammation: a post hoc analysis of the BOREAS and NOTUS trials.

Listen to this summary

This post hoc analysis of the BOREAS and NOTUS trials asked whether dupilumab improves lung function in patients with COPD and type 2 inflammation. Over 52 weeks, dupilumab produced early and sustained gains in pre- and post-bronchodilator FEV1, FVC, FEV1/FVC, and FEF25-75 compared with placebo, with larger benefits in patients with higher baseline eosinophil counts or FeNO and benefits seen regardless of smoking status or emphysema.

MeiLan K Han, Klaus F Rabe, Frank C Sciurba, Claus F Vogelmeier, Surya P Bhatt, Antonio Anzueto, Mona Bafadhel, Stephanie A Christenson, Francesca Puggioni, Jinping Zheng, Alberto Papi, Dave Singh, Deborah Bauer, Mena Soliman, Jigna Heble, Nicola A Hanania

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play